Although the sample size of patients on anti-PD-L1 was small (13 and 9 patients in the discovery and validation sets, respectively), the combination anti-PD-L1 regimen showed a higher MPR than the combination anti-PD-1 as a neoadjuvant treatment for patients with NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.